Amycretin

Areas of active research — not promised effects

Each tag links to other compounds with research into that goal. Research use only: these are areas of study, not human-use claims.

Related by research scope · open each to compare

Amycretin has no FDA approval or licensed indication. It is lawfully administered only within authorised clinical trials under an Investigational New Drug (IND) application. It is not on FDA Category 2 (503A/503B restricted-compounding) lists (fda19=false) because it is not a compoundable substance — it remains a Novo Nordisk proprietary investigational drug. Outside clinical trials, possession or administration would lack legal basis under US law.

No verifiable third-party COA path in this market

Transparent blend · bci-1.0 · never paid-placement

Primary name

Amycretin

Origin

Synthetic peptide designed by Novo Nordisk; covalently links analogs of glucagon-like peptide-1 (GLP-1) and amylin (islet amyloid polypeptide, IAPP) into a single molecule. Development code NN 9487; INN zenagamtide.

Sequence not available in current seed.

Vial sizes

null mg

Purity grades

Salt forms

Free base (primary)

• GHS hazard class on file
• PPE & spill response
• Disposal guidance
• Not-for-human-consumption posture

How much research exists, and of what maturity — never a verdict on whether it works.

Mechanism of action

• Amycretin simultaneously activates GLP-1 receptors and amylin receptors (calcitonin receptor / RAMP co-receptor complexes), producing additive suppression of food intake and body weight
• GLP-1 receptor signalling reduces appetite via central pathways in the nucleus tractus solitarius and peripheral slowing of gastric emptying, while amylin receptor co-agonism engages POMC neurons and suppresses orexigenic NPY/AgRP circuits in the arcuate and dorsomedial hypothalamus
• Fatty-acid acylation enables reversible albumin binding, extending the half-life to support once-weekly subcutaneous or once-daily oral dosing
• In Phase 1b/2a trials, once-weekly subcutaneous administration at doses up to 60 mg produced up to 24% mean body-weight reduction at 36 weeks versus approximately 1% on placebo, substantially exceeding reductions seen with GLP-1 mono-agonists at comparable timepoints

Pharmacokinetics (ADME)

Half-life

Compatible with once-weekly SC dosing; specific t1/2 value not disclosed in publicly available Phase 1 summaries as of May 2026

PK–PD note: Fatty-acid acylation mediates albumin binding to prolong circulating exposure. Oral bioavailability achieved at doses of 1–50 mg/day in Phase 1; PK parameters (AUC, Cmax) were secondary endpoints in b…

Reading the evidence

• Evidence quality and gaps vary by application — see the cited grades above.
• Indexed-article counts span all evidence tiers, not only completed human trials.
• No first-party human-dosing, efficacy, or benefit claims are made here.

Key reviews & evidence-gap sources

• Efficacy and safety of incretin co-agonists: Transformative advances in cardiometabolic healthcare (PubMed 40949933) — Narrative evidence review covering GLP-1/amylin co-agonists including amycretin; cites early-phase clinical data.
• The effect of amycretin on body weight and metabolic dysfunction in mice and rats (PMC12309853 / PMID 40706446) — Preclinical mechanistic + animal (DIO rats/mice) study; reports GLP-1, amylin and calcitonin receptor activation and 47% energy-intake reduction in DIO rats.
• Gasiorek et al., Lancet 2025;406:135-148 — first-in-human phase 1 oral amycretin (PMID 40550229) — Phase 1 RCT (NCT05369390), 144 participants; safety/tolerability/PK/PD; supports further weight-loss investigation.
• Phase 1b/2a subcutaneous amycretin RCT (NCT06064006), Lancet 2025 (PMID 40550231) — 125-participant randomized placebo-controlled trial; up to 36 weeks; safety consistent with GLP-1/amylin agonists.

1 registered trial — 0 currently recruiting.

Phase 1
NCT06049329
A Research Study of How a New Medicine Called Amycretin, Given as Tablets, Works in Japanese Men With Obesity

COMPLETED

Summary (literature)

In Phase 1 (oral, n=144) and Phase 1b/2a (subcutaneous, n=125) trials published in The Lancet (2025), the most common adverse events were gastrointestinal: nausea (~82% SC; dose-dependent with oral), vomiting (~53% SC), and diarrhoea (~41% SC). Events were predominantly mild to m…

WADA status

Not specifically listed on the WADA 2026 Prohibited List. GLP-1 receptor agonists (e.g., semaglutide, tirzepatide) are currently in WADA's monitoring programme …

Dominant research route: SC and PO developed in parallel; SC has more mature Phase 1b/2a data (36-week, up to 60 mg) while PO has Phase 1 first-in-human and Phase 2 data; both advancing to Phase 3

Once-weekly subcutaneous amycretin up to 60 mg in adults with overweight/obesity (Phase 1b/2a, NCT06064006); 125 participants, treatment up to 36 weeks

Bioavailability: Once-weekly SC administration; dose range studied 1.25–60 mg; mean bodyweight reductions up to 24.3% at 60 mg (week 36) vs placebo

Phase 1b/2a randomised, placebo-controlled, double-blind trial assessing safety, tolerability, pharmacokinetics, and proof-of-concept after SC administration; results published in The Lancet 2025 (Dahl et al.)

Once-daily oral amycretin tablets in adults with overweight/obesity (Phase 1 first-in-human, NCT05369390); 144 participants, up to 12 weeks; also Phase 2 in type 2 diabetes

Bioavailability: Oral peptide co-formulated with SNAC (salcaprozate sodium; sodium N-[8-(2-hydroxybenzoyl)amino]caprylate) as a permeation enhancer to enhance oral absorption; once-daily tablet dosing

First-in-human Phase 1 randomised, placebo-controlled, double-blind trial of oral amycretin; results published in The Lancet 2025 (Gasiorek et al.); oral formulation distinct from SC product

Amycretin administration in diet-induced obese (DIO) mice and rats; 21-day treatment in DIO rats

Bioavailability: Preclinical pharmacological characterisation; amycretin activated human, mouse, and rat GLP-1, amylin, and calcitonin receptors in cell-based systems

Preclinical study in mice and rats characterising effects on body weight, energy intake, insulin sensitivity, and MASLD; supported advancement to clinical trials

Animal & human figures are kept visibly separate so studied animal doses are never misread as human guidance.

Sorted A–Z by vendor — never by price

Researched storefront prices, bucketed

What each test proves — general guidance, plus this compound's researched purity data

Independent labs cited for this compound

No recalls, seizures, or counterfeit-specific enforcement actions naming amycretin were found in FDA warning-letter, import-alert, or health-fraud-seizure records as of the search date. Amycretin remains an investigational compound with no approved commercial product to recall; any 'amycretin' sold through research-compound vendors is by definition unapproved and outside FDA quality oversight.

Buyer red-flag checklist

• Amycretin is not FDA-approved and has no approved NDA; any product labeled 'amycretin' sold for human use is an unapproved new drug.
• Products labeled as amycretin sold through online research-compound vendors are not FDA-regulated and carry unknown contamination, dosing, and safety risks.
• No independent third-party lab tests (Janoshik/MZ Biolabs/Finnrick) specific to amycretin were located; purity and identity of grey-market 'amycretin' cannot be corroborated.
• As a novel first-in-class unimolecular peptide with limited public reference standards, grey-market synthesis carries elevated risk of misidentification, truncation, or substitution.
• FDA has issued warning letters to multiple peptide/GLP-1 vendors (e.g., USApeptide.com, Gram Peptides, GLP-1 Solution) for selling unapproved new drugs marketed with 'research use only' disclaimers — a pattern directly relevant to any amycretin grey-market listing.
• FDA Import Alert 66-80 enables detention without physical examination of GLP-1 APIs with quality concerns at the U.S. border.

GMP vs research-grade: the chemistry (SPPS + HPLC + MS) is identical — the difference is the quality system.

Underdosing / mislabeling: No independent third-party lab tests (Janoshik, MZ Biolabs, Finnrick, or equivalent) specific to amycretin were located in public databases or vendor COA ledgers. The Janoshik public test database (public.janoshik.com) could not be retrieved (HTTP 403), and no vendor COA naming amycretin/NNC0487-0111 was found among the peptide vendors surveyed. Because amycretin is a novel, unapproved, first-in-class peptide with no reference standard widely available to grey-market labs, identity and purity claims on any 'amycretin' research product cannot be independently corroborated at this time.

• FDA Import Alert 66-80 (green list) targets GLP-1 active pharmaceutical ingredients (APIs) with potential quality concerns for Detention Without Physical Examination at the border. The alert does not name amycretin specifically but applies to GLP-1-class APIs from non-compliant foreign manufacturers; as an unapproved investigational GLP-1/amylin co-agonist, amycretin API would not qualify for the compliant-manufacturer exemption.66-80
• An RUO label is not an import exemption — CBP judges actual intended use.
• Lyophilized powder is ambient-stable in transit; temperature control needed for > 7-day transit.
• US-warehouse vendors dodge import scrutiny — they cost more but ship more reliably.

Every item dated & sourced

Not prohibited. Amycretin is a GLP-1 and amylin receptor agonist; GLP-1 receptor agonists are included in WADA's monitoring program but are not on the Prohibited List. Amycretin is not specifically named on the WADA Prohibited List.

No granted patents identified in current seed. Composition-of-matter coverage is limited given the peptide's synthetic origin.

• IACUC / IRB research context
• RUO buyer responsibilities & documentation
• Veterinary / alternative-use where lawful
• Jurisdiction-aware "who may lawfully obtain"

What people discuss

Reported concerns — discussion, not established effects

Reading caveats

• early-phase enthusiasm / extrapolation from small trials
• stock-price speculation framing
• comparison-to-approved-drugs framing (Ozempic/Wegovy)
• investor-oriented discourse over patient-experience discourse

Manually researched from reddit, youtube, x— theme weights are research estimates, not live counts; aggregated & de-identified. No individual posts, quotes, or usernames are ever shown.

Relative research / market volume — populated once the activity stream is wired

Inline tooltips for lyophilized, RUO, EU/mg, SPPS, 503A and more.

Toggle plain-language ↔ scientific in the header.

• How to read a COA
• Free base vs acetate
• Understanding evidence grades

First-in-class unimolecular GLP-1 and amylin receptor dual agonist (Novo Nordisk) in Phase 3 development for obesity and type 2 diabetes. Approximately 15 articles are indexed (literature last scanned 2026-05-29). US regulatory status: Investigational (IND-stage; unapproved). Research use only.

Emitted as JSON-LD: ChemicalSubstance · BreadcrumbList · FAQPage.

• Price-drop & back-in-stock alerts
• Regulatory-change email digest
• Print / share this datasheet